probiotix health Regulatory News (PBX.PL)

21 January 2026

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Trading Update

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a trading update for the financial year ended 31 December 2025.

Key highlights*:

· Sales +45% to £2.72m (2024: £1.88m)

· Gross profit +46% to £1.46m (2024: £997,000) 

· EBITDA loss from continuing operations down 31% to £445,000 (2024: £642,000)**

· Gross Profit margin increased to 54% (2024: 53%)

· Strong cash balance of £1.27m at year-end

 · Record Q1 2026 order book +110% at £1.3m

* Figures are subject to audit

** Before share based payment expense

Review of the year

We are delighted to report that 2025 was a year of continued and satisfactory progress for ProBiotix, delivered against our stated strategy and operational objectives. The strong trading performance reflects growing commercial traction across our core markets, supported by both new customer acquisition, and continued positive growth from already established customer partnerships. Alongside the commercial momentum, we implemented a number of internal initiatives to enhance operational scalability, and improve the path to profitability.

Revenue growth was primarily driven by increased traction in the USA and Europe. In China, the recently established partnership with Kemin performed strongly during the year, benefiting from the execution of Kemin's highly effective market positioning strategy. The relationship with key US customer Seed Health remains robust, delivering continued growth. At the same time, we further reduced the Company's dependency on a few key customers by the addition of potential cornerstone customers such as Wellizen (Australia), RevivaBio (Sweden) and NutriWow (China).

Significantly, ProBiotix has made material progress towards profitability during the year. EBITDA losses were reduced by 31% to £445,000 in 2025 (2024: £642,000), fully in line with our stated strategic objectives. The gross profit margin edged higher to 54% (2024: 53%), with multiple initiatives underway to further enhance margins in 2026 and beyond, including the conclusion of our regional Contract Manufacturing Organisation (CMO) strategy to improve supply security, closeness to market and cost optimisation.

During the year, ProBiotix launched a new menopause-focused women's health concept, based on our LPLDL® strain - YourBiotixMH. Early commercial traction has been positive, with 27 projects currently open, a number of which are in detailed discussion, and the first two product launches anticipated for early 2026. The interest in these new products is driven by growing consumer focus on science-backed solutions in women's health and healthy ageing.

Commercial traction continued to build throughout the year. In 2025 we generated a significant increase in enquiries, with over 280 'qualified leads' (2024: 190). This has been driven by our participation in major global industry events, including SupplySide Global (USA), Vitafoods Europe (Spain) and Vitafoods Asia (Thailand). The active customer portfolio expanded by approximately 50%, following the successful onboarding of new customers across multiple geographies.

We also continued to strengthen our scientific and clinical foundations. Applications were submitted for ethical committee approval for two new clinical trials. The first, a three year study expected to include over 200 participants, will investigate the potential benefits of LPLDL® in individuals with pre-diabetes, type I diabetes and type II diabetes. A successful outcome could support future expansion of LPLDL® into the preventive pre-diabetes category. The second trial, with approximately 60 participants, is designed to further reinforce the clinical evidence supporting the role of LPLDL®  in cardiometabolic health and cholesterol reduction.

Geographic expansion progressed well during the year, with entry into the Korean market through the launch of our CholBiome X3, a finished product containing the Company's proprietary LPLDL® ingredient. The launch was executed in partnership with P.Bros, Korea's leading influencer-driven online pharmacy platform.

We remain fully funded to deliver our growth aspirations and a key milestone during the year was our Admission to the Apex Segment of the Aquis Stock Exchange. This segment is only available to larger, more established businesses, and we were delighted to fulfill the required criteria. With this validation, we look forward to maintaining our dialogue with all our investors.

Outlook for 2026

We have entered the current financial year with a great deal of momentum, and a Q1 2026 order book which has more than doubled to a record £1.3 million, comprised of a much broader customer base. New customer wins and increased re-ordering activity from existing customers, further validate the consumer appeal of LPLDL®.

During 2026, the Company's commercial focus will include accelerated expansion across the Asia-Pacific region, which management believes will be a key driver of short- and medium-term revenue growth as well as serve as risk mitigation towards the re-ignited trade war between the USA and UK/Europe.

In Europe, we see an increasing opportunity for LPLDL®, supported by potential regulatory changes that may restrict the use of Monacolin K (from Red Yeast Rice) as a cholesterol-lowering ingredient in supplements. We are already engaged in a number of active projects with several leading European brands to replace Red Yeast Rice with LPLDL® within their products, with the first material product launch by a major European consumer brand expected in the first half of 2026.

In the US, the Company anticipates the conversion of a number of late-stage projects into commercial contracts, further expanding the growing customer base in the region. We believe the current trade situation might potentially have a negative short term impact on the speed at which we can penetrate the US-market in 2026. However, no long term impact is anticipated, with the mitigation measure of local manufacturing being executed.

Steen Andersen, CEO of ProBiotix, commented: "The growth trajectory of ProBiotix continues apace, with notable growth in a number of territories, driven by increasing awareness of our products.

Our organisational structure is now largely complete, which provides a robust platform to augment future expansion. We have established a highly scalable business with global appeal, and our internal focus for 2026 will be on further embedding our processes and systems to support our anticipated growth.

With a record order book, a broadening customer base and current strong enquiry levels, we remain confident in our future prospects."

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a singular approach: discovering groundbreaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.